Key Points for Compliance Management in Bioreagent Procurement and Risk Control in Cold Chain Transportation

Overview of Compliance Requirements in Biological Reagent Procurement

The compliance requirements involved in the procurement of biological reagents vary depending on the intended use of the product. Reagents used for scientific research typically need to comply with laboratory safety and quality management systems; reagents used for in vitro diagnostics or drug production quality control may involve medical devices, Good Manufacturing Practice for drugs, or relevant industry standards. Procurement personnel should not rely solely on verbal commitments from suppliers, but should clarify the admission requirements for each category of reagents based on the product's intended use, regulatory classification, and the organization's own quality system.

Common compliance risks include: misuse of research-grade reagents for clinical testing, procurement of unapproved reference standards or quality control materials, key reagents lacking Chinese labels or instructions, and cold chain transport temperature deviations that have not been assessed. It is recommended to establish in the procurement policy the principle of "classified management and tiered approval," setting different approval and acceptance requirements for reagents of different risk levels.

Management of Supplier Licenses and Product Qualification Documents

Before signing a procurement contract, the supplier's legal business qualifications should be collected and reviewed. For reagents involving medical devices, the supplier should hold the corresponding business filing or business license, and the product should have a medical device registration certificate or filing certificate. For non-medical-device research reagents, suppliers may be required to provide a business license, quality system certification, and product quality standard documentation. For imported reagents, attention should also be paid to certificates of origin, import customs declarations, or agent authorization documents.

It is recommended to establish an electronic license archive with expiration reminders to avoid the use of expired qualifications. For each procurement, suppliers may be required to provide the batch-specific quality inspection report or certificate of conformity along with the goods. Qualification documents should correspond one-to-one with product batch information to ensure rapid traceability in the event of quality issues.

Cold Chain Transport: Key Stages from Dispatch to Receipt

Many biological reagents are temperature-sensitive, such as enzymes, antibodies, cytokines, and reference standards, which typically require transport at 2–8°C or lower. Cold chain transport risks often arise during transfer, temporary storage, and the final leg of delivery. The purchaser should require suppliers to use validated insulated packaging, such as foam boxes with ice packs, dry ice, or phase change materials, and to include temperature recording devices. For reagents requiring ultra-low temperature storage, such as certain nucleic acid or protein standards, dry ice shipping may be necessary, and the amount of dry ice should be sufficient to maintain the temperature until arrival.

Upon receipt, the outer packaging should be inspected for obvious damage, and the temperature records should be checked for completeness. If ice packs are used, observe whether they remain solid or partially melted; if dry ice is used, check whether any dry ice remains. Temperature recorder data should be downloaded and archived as one of the acceptance criteria.

Temperature Control Records and Deviation Handling Procedures

Temperature control records are objective evidence for determining whether reagent quality has been affected. A common practice is to require suppliers to provide temperature data during transport, or for the receiving party to perform on-site temperature measurement using a calibrated thermometer. In cases of missing records or temperature excursions beyond the allowed range but of short duration, the reagents should not be directly judged as acceptable; instead, a deviation assessment should be initiated, with the quality or technical department determining whether to release the reagents based on reagent stability data.

The deviation handling procedure generally includes: recording the anomaly, isolating the affected reagents, notifying the supplier, assessing the scope of impact, deciding on return or concessionary acceptance, and generating a written report. Any concessionary acceptance should have a clear technical basis and approval record to avoid overlooking potential risks due to urgency of use.

Document Verification and Retention Sample Recommendations During Acceptance

When accepting biological reagents upon arrival, in addition to verifying the product name, specification, quantity, lot number, and expiration date, it is also necessary to check whether the accompanying documents are complete, such as COA, MSDS, instructions, and import customs declarations. Document information should be consistent with the physical labels, especially the lot number and expiration date. For key reagents, it is recommended to retain samples during acceptance; the retention quantity and storage conditions should be sufficient to meet subsequent retesting or traceability needs.

Retention sample management should have a ledger recording the retention date, usage period, and storage location. Retention sampling is not mandatory for all reagents, but for quality control materials, reference standards, diagnostic antibodies, or key enzymes, retention samples help reproduce the quality status in the event of a dispute and are an important supplement to compliance management.

Compliance Risk Self-Inspection and Continuous Improvement

Laboratories or enterprises should periodically conduct compliance self-inspections of the biological reagent procurement process, checking whether supplier licenses are within their validity period, whether cold chain transport records are complete, whether acceptance records are standardized, and whether deviation handling is closed-loop. Self-inspection may be conducted through spot checks or special audits, with emphasis on high-risk reagents and frequently procured categories.

For issues identified during self-inspection, corrective measures should be developed and follow-up implementation tracked. At the same time, procurement policies and supplier management requirements can be continuously optimized in light of updates to industry regulations and internal quality events.Compliance is not a one-time task but a dynamic process that runs through the entire procurement workflow. Only through continuous improvement can quality and compliance risks in the reagent supply chain be effectively reduced.